SCHEMBL16615508

SCHEMBL16615508

C=CC(C)(C)C(=O)c1ncc(Br)c(OCCCC)c1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 4/20 0.37
THRB P10828 4/20 0.37
SLC6A5 Q9Y345 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
ALDH1A1 P00352 2/20 0.32
AR P10275 1/20 0.31
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31
KMT2A Q03164 1/20 0.31
PTPN1 P18031 1/20 0.31
AURKB Q96GD4 1/20 0.31
TBK1 Q9UHD2 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ESR1 P03372 1/20 0.30
S1PR1 P21453 1/20 0.30
S1PR3 Q99500 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18012155 0.82 THRA (0.38) THRATHRBSLC6A5SMN1; SMN2ALDH1A1
SCHEMBL17997116 0.80
SCHEMBL16615619 0.80 THRA (0.36) THRATHRBSLC6A5SMN1; SMN2ALDH1A1
SCHEMBL16615510 0.80 THRA (0.36) THRATHRBSLC6A5SMN1; SMN2ALDH1A1
SCHEMBL16615602 0.76 THRA (0.33) THRATHRBSLC6A5ARCCNB2
SCHEMBL16615603 0.76 THRA (0.33) THRATHRB
SCHEMBL16615507 0.74 THRA (0.32) THRATHRBSMN1; SMN2ALDH1A1MEN1
SCHEMBL16615615 0.71 THRA (0.30) THRATHRB
SCHEMBL16615504 0.71 THRA (0.38) THRATHRBSMN1; SMN2ALDH1A1MEN1
SCHEMBL16615642 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160228419-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-11 US disclosed
WO-2015048363-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228419-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS NQO2, CYP3A5, QTRT1 THRA 3454/4885THRB 3636/4885SLC6A5 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.